Valneva announced the initiation of a Phase 1/2 clinical study for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
Toggle Navigation
- Research
Back- Research at Vienna BioCenter
- Research Entities
- Research AreasResearch AreasOpen SubmenuBack
- Anthropogenic Evolution
- Biochemistry, Biophysics, Structure
- Cell and Chromosome Biology
- Cognitive and Behavioral Biology
- Computational Biology, Genomes and Evolution
- Disease Mechanisms, Immunology, Pathogens
- Gene Regulation, RNA, Epigenetics
- Microbiology and Environmental Systems Science
- Neurobiology
- Plant Sciences
- Stem Cells, Development, Regeneration
- Research Groups
- Key DiscoveriesKey DiscoveriesOpen Submenu
- Recent Research Highlights
- Covid-19Covid-19Open Submenu
- VBCF
- CompaniesBack
- Companies at Vienna BioCenter
- Biotech CompaniesBiotech CompaniesOpen SubmenuBack
- a:head
- Ablevia Biotech
- ACCANIS Biotech
- ADvantage Therapeutics
- Affiris AG in Liqu
- Akribes
- Ares Genetics
- Austrianni
- BioNTech R&D Austria
- Bird-C
- bit.bio discovery GmbH
- CALYXHA Biotechnologies
- ChanPharm
- EUCODIS Bioscience
- Eveliqure
- Evercyte
- Exscientia
- G.ST Antivirals
- Haplogen
- Hookipa Pharma
- invIOs
- JLP Health
- Lexogen
- Miti Biosystems
- MyeloPro Diagnostics and Research GmbH
- Myllia Biotechnology
- OncoOne
- Origimm
- Phenaris
- Pregenerate
- Proxygen
- QUANTRO Therapeutics
- SCARLETRED
- TAmiRNA
- Thermo Fisher Scientific
- Tridem Bioscience
- Valneva
- X4 Pharmaceuticals
- YGION Biomedical GmbH
- Service CompaniesService CompaniesOpen Submenu
- Business IncubatorsBusiness IncubatorsOpen Submenu
- Scientific AssociationScientific AssociationOpen Submenu
- Education
- Career
- About